PolarCool

The med-tec company PolarCool AB (publ) continues to establish PolarCap® in European professional ice hockey, by signing a two-year agreement with top Swiss club, SC Bern.

PolarCool develops and markets the product PolarCap®, which alleviates the effects of concussion. The primary users of PolarCap® include sports clubs, organizations, and facilities in contact sports such as ice hockey, rugby, football, and handball, as well as other sports with an increased risk of concussion.

In addition to the league-wide agreement with the Swedish Hockey League, PolarCool has agreements with top teams in Finland, Denmark, Norway, Germany and Switzerland. In the Swiss top league, the National League, SC Bern is now the second team to use PolarCap to treat concussions, alongside HC Davos.

The agreement with SC Bern is strategically important for the company's continued establishment in the National League, even if the financial significance of individual agreements is limited. SC Bern will use the PolarCap for the rest of the 2023 season in an initial evaluation period, with the option to continue into a two-year commercial agreement following the season.

SC Bern General Manager Andrew Ebbett comments;

- We now look forward to including PolarCap in our routines around concussions. The scientific evidence is impressive and it's satisfying to now be able to provide improved treatment possibilities to our players.

PolarCool's CEO Erik Andersson comments;

- It is gratifying that SC Bern has chosen to include PolarCap in their management and treatment of concussions. In our goal to establish PolarCap as a treatment within Swiss ice hockey, adding another influential hockey giant as PolarCap users will aid momentum and broaden interest among other clubs.